Dose escalation of cyclophosphamide in patients with breast cancer: consequences for pharmacokinetics and metabolism

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
D BusseH K Kroemer

Abstract

The alkylating anticancer agent cyclophosphamide (CP) is a prodrug that undergoes a complex metabolism in humans producing both active and inactive metabolites. In parallel, unchanged CP is excreted via the kidneys. The aim of this study was to investigate the influence of dose escalation on CP pharmacokinetics and relative contribution of activating and inactivating elimination pathways. Pharmacokinetics of CP were assessed in 12 patients with high-risk primary breast cancer who received an adjuvant chemotherapy regimen that included four courses of conventional-dose CP (500 mg/m2 over 1 hour every 3 weeks) followed by one final course of high-dose CP (100 mg/kg over 1 hour). Plasma concentrations of CP were analyzed by high-performance liquid chromatography (HPLC), 24-hour urinary concentrations of CP, and its inactive metabolites (carboxyphosphamide, dechloroethylcyclophosphamide [dechlorethylCP], ketocyclophosphamide [ketoCP]) were determined by 31-phosphorus-nuclear magnetic resonance (31P-NMR)-spectroscopy. There was no difference in dose-corrected area under the concentration-time curve (AUC) (216 v 223 [mumol.h/[mL.g]), elimination half-life (4.8 v 4.8 hours), systemic clearance (79 v 77 mL/min) and volume of distributi...Continue Reading

Citations

Oct 3, 1998·Clinical Pharmacology and Therapeutics·S RenJ T Slattery
Jul 13, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·E MantadakisB A Kamen
Oct 19, 2000·Anti-cancer Drugs·A D HuitemaJ H Beijnen
Dec 3, 2003·Bone Marrow Transplantation·Y Nieto, W P Vaughan
Apr 4, 2008·Pain Medicine : the Official Journal of the American Academy of Pain Medicine·Douglas J WeschulesSteven Richeimer
Dec 17, 2009·Analytical Sciences : the International Journal of the Japan Society for Analytical Chemistry·Yuki ImuraEtsuro Yoshimura
Mar 8, 2019·Journal of Chemotherapy·MengXue LiFang Qi
Nov 25, 2000·Breast Cancer : the Journal of the Japanese Breast Cancer Society·T TajimaM Kubota
Jun 18, 2002·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Celeste LindleyEdward L LeCluyse
Feb 18, 2005·Pediatric Nephrology : Journal of the International Pediatric Nephrology Association·Udo VesterPeter F Hoyer
Dec 23, 2004·Journal of Mathematical Biology·M ScholzM Loeffler
Aug 24, 2005·The Pharmacogenomics Journal·R TimmI Cascorbi
Sep 30, 2009·Nature Reviews. Clinical Oncology·Ashkan EmadiRobert A Brodsky
Aug 3, 2013·Cancer Chemotherapy and Pharmacology·Meagan J BemerJeannine S McCune
Mar 22, 2002·The Journal of Pharmacology and Experimental Therapeutics·Thomas E MürdterBernhard Sperker
Feb 21, 2006·British Journal of Haematology·Markus ScholzUNKNOWN German High Grade Non-Hodgkin Lymphoma Study Group (DSHNHL)
Oct 20, 2005·Clinical Pharmacokinetics·Milly E de JongeJos H Beijnen
Feb 16, 2005·Anti-cancer Drugs·Milly E de JongeJos H Beijnen
Jul 3, 2008·Pediatric Nephrology : Journal of the International Pediatric Nephrology Association·Sheetal V ShardaSuraksha Agrawal
Dec 14, 2006·Therapeutic Drug Monitoring·Priska KaufmannStephan Krähenbühl
Jan 18, 2012·Journal of Clinical Pharmacology·Melanie S Joy
May 10, 2000·Clinical Pharmacokinetics·A V Boddy, S M Yule
Oct 23, 1998·Pharmacology & Toxicology·K VillikkaP J Neuvonen
Oct 1, 2010·Journal of Occupational and Environmental Medicine·Thomas H ConnorMelissa A McDiarmid
Jun 2, 2004·Clinical Pharmacokinetics·Masatoshi TomitaKenichi Tanaka
May 8, 2010·Expert Opinion on Drug Metabolism & Toxicology·Bérénice GiraudAngelo Paci
Oct 13, 2000·Fundamental & Clinical Pharmacology·L Belfayol-PisantéF Fauvelle
Jul 7, 2015·Expert Review of Clinical Pharmacology·Xiaoyan YangAlexander A Vinks
Apr 25, 2002·Journal of Pediatric Hematology/oncology·Carlos Rodríguez-GalindoCharles B Pratt
Jan 6, 2006·Drug Metabolism Reviews·Jing ZhangYi-Zhun Zhu
Jan 18, 2011·Annals of Oncology : Official Journal of the European Society for Medical Oncology·B Glimelius, M Lahn

❮ Previous
Next ❯

Related Concepts

Related Feeds

Birth Defects

Birth defects encompass structural and functional alterations that occur during embryonic or fetal development and are present since birth. The cause may be genetic, environmental or unknown and can result in physical and/or mental impairment. Here is the latest research on birth defects.